<DOC>
	<DOC>NCT00350792</DOC>
	<brief_summary>A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer</brief_summary>
	<brief_title>Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Pathologically confirmed Non Small Cell Lung Cancer Stage IIIb (not amenable to radiotherapy treatment) or Stage IV No previous chemotherapy for lung cancer Men and women &gt; or = 70 years At least one unidimensionally measurable lesion (Response Evaluation Criteria In Solid Tumors [RECIST]criteria) Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 Treatment within the last 30 days with a drug that has not received regulatory approval Serious systemic disorders Inability to discontinue administration of aspirin or antiinflammatory non steroid Concurrent administration of any other antitumor therapy Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>